SkyePharma
Article Abstract:
SkyePharma has developed a range of techniques for drug delivery, and has contracts with major pharmcaeutical companies. Risks are reduced because of this wide range, and large pharmacetical companies may see SkyePharma as a one-stop shop. SmithKline Beecham has acquired an equity stake in SkyePharma, as has Novartis. SkyePharma has previously had problems, but appears to offer potential for investors as it develops its range of technologies for drug delivery.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
Skyepharma
Article Abstract:
Skyepharma specialises in drug delivery, and its Solarase has been approved in the US.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
SkyePharma
Article Abstract:
SkyePharma faces less risk than most biotechnology firms, and has arranged a finance deal.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 2001
User Contributions:
Comment about this article or add new information about this topic: